In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
From July 1987 to January 1988, 452 cefoperazone-resistant bacterial isolates were identified among strains subjected to routine susceptibility testing in a clinical microbiology laboratory. The 452 isolates were tested for susceptibility to cefoperazone, sulbactam, and a 2:1 combination of these drugs by agar dilution techniques. The greatest benefit of the cefoperazone-sulbactam combination was noted against Bacteroides spp. and Acinetobacter spp. The combination demonstrated clinically significant synergism against approximately 20% of strains of Pseudomonas aeruginosa.
Eliopoulos
G M
GM
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
Klimm
K
K
Ferraro
M J
MJ
Moellering
R C
RC
D000150:Acinetobacter / Q000187:drug effects; D001419:Bacteria / Q000187:drug effects*; D001439:Bacteroides / Q000187:drug effects; D002438:Cefoperazone / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects; D006801:Humans; D011549:Pseudomonas / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology*
D002438:Cefoperazone; D013407:Sulbactam